Northfield Blood Substitute Rejected by FDA
The Food and Drug Administration refused to approve the human blood substitute, Polyheme, for use in trauma patients suffering from severe blood loss.
12:28AM 05/01/09
Northfield, Polyheme Not Long for This World
An FDA decision to not convene a panel of blood experts to review Northfield Labs' Polyheme is a signal the agency already has decided to reject the blood substitute for approval.
12:21AM 03/18/09
Biotech Stock Mailbag: My Say on Sequenom
Travis T. takes umbrage with an article on Sequenom's latest Down syndrome data.
06:59AM 01/30/09
Blood Sub or Not, Northfield's a Negative
With the odds stacked against Polyheme being approved, investors should think hard before chasing this stock.
06:05PM 01/22/09
What's Working -- and What Isn't (RealMoney.com $)
As we look ahead to a bumpy year, let's assess where we are now.
11:01AM 01/12/09
New Year, New Model Portfolio Addition (Biotech Select $)
Establishing a position in this beaten-down stock, as there is potential to be found in one of its experimental drugs.
07:55AM 12/31/08
Biotech Mailbag: Xoma Looks Promising
Xoma's promising study results on a diabetes drug makes it more likely it will find a partner.
03:14PM 09/12/08
Biotech Mailbag: Xoma Looks Promising (RealMoney.com $)
Xoma's promising study results on a diabetes drug makes it more likely it will find a partner.
06:58AM 09/12/08
Biotech Notebook: Progenics, Wyeth, Introgen
Projecting potential market share for newly approved Relistor; monitoring exec moves at Introgen; and more.
09:26AM 04/30/08
Feuerstein's Biotech-Stock Mailbag
Glaxo may face a tough sell with newly approved Treximet; additional feedback on Elan, and more.
09:00AM 04/19/08
Feuerstein's Biotech-Stock Mailbag
Vertex's cystic fibrosis compound shows promise, but be cautious in your enthusiasm. Also, an update on the quest for blood substitutes.
12:01PM 03/29/08
Feuerstein's Biotech-Stock Mailbag
This week, questions on Viropharma, Indevus, ArQule and (briefly) Northfield Labs.
09:43AM 08/11/07
Wall St. Confidential: How Cramer Banks on Biotech
By Farnoosh Torabi | By Jim Cramer
What biotech names are poised for gains?Plus why you can't bet on the FDA.
12:29AM 08/07/07



Connect with TheStreet